Cervical cancers after human papillomavirus vaccination

Obstetrics and Gynecology

Volumn 114, Issue 1, 2009, Pages 174-175

  Joura, Elmar A ^a   Garland, Suzanne M ^b  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; CANCER SCREENING; CLEAR CELL CARCINOMA; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; LETTER; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VACCINE FAILURE; ADOLESCENT; ADULT; FEMALE; IMMUNOLOGY; NOTE; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 67651021727     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181aa8f9f     Document Type: Letter

References (6)

1. Beller U, Abu-Rustum NR. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 2009;113:550-2.
2. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357:1579-88.
3. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
4. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369: 1693-702.
5. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 -26 years. J Infect Dis 2009;199:936-44.
6. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. JNatl Cancer Inst 2008;100:308-20.